APPLIED STEMCELL
Founded in 2008 to provide industry and academic researchers with the ability to leverage the power of induced pluripotent stem cells (iPSC) and gene editing, Applied StemCell continues to use our innovative technologies to power the discovery and development of advanced therapeutics. Our products and services enable the full spectrum of basic research to early-stage GMP manufacturing—including disease modeling, iPSC services, library construction, drug screening, and nonclinical and pre-IND studies—and our patented technologies ensure a clear IP path to commercialization.
INDUSTRY INSIGHTS
-
Unlocking Allogeneic Cell Therapy: Exploring Durable Approaches
Learn how genome engineering and iPSCs are being used to overcome the critical challenges of durability and host immune clearance in both clinical and preclinical settings for allogeneic cell therapies.
-
The Advantages Of Off-The-Shelf GMP iPSCs With A DMF
Learn how off-the-shelf, GMP-grade iPSC lines with a Drug Master File (DMF) can accelerate cell therapy development, streamline regulatory approval, and reduce time and cost to clinic.
-
Efficient Mammalian Cell Engineering For Difficult Protein Expression In 4-6 Weeks
By leveraging cells equipped with an existing TARGATT™ landing pad, we demonstrate how inducible expression can be efficiently achieved within just 4-6 weeks after donor plasmid creation.
-
The Future Of Allogeneic Cell Therapy: Hypoimmunogenic Donor Cells
Explore how TARGATT™ gene editing and HLA-F technologies are revolutionizing hypoimmunogenic cell development for scalable allogeneic therapies.
CONTACT INFORMATION
Applied StemCell
521 Cottonwood Dr Suite 111
Milpitas, CA 95035
UNITED STATES
Phone: (408) 773-8007
Contact: A. Pia Abola, Ph.D., Director of Marketing
SOLUTIONS
-
Are you in need of an experienced and flexible GMP service provider that can assist you with the development and clinical manufacturing of your gene or cell therapy with expert CMC support?
-
Master and working cell banks can be customized to your project needs for size, concentration, and quality in-process and release testing.
-
iPSC generation is a complex process of reprogramming adult somatic cells into a pluripotent, embryonic stem cell-like stage.
-
Go bigger, stay on target, and engineer the mammalian cell lines that get the job done.
-
A Class 2 Type V Cas9 nuclease, Mad7 is ideal for product development that relies on genome editing.
-
A quick overview of this industry-changing technology as well as the newer Cas9 variants that expand its use.
-
Simple, scalable genome engineering at the naturally occurring S-SELeCT™ safe harbor locus.
-
At Applied StemCell, we specialize in producing high-quality differentiated cells from well-characterized normal iPSCs. Our cells offer the biorelevance of primary cells while eliminating the challenges associated with sourcing and variability across batches.
-
At Applied StemCell, we specialize in providing high-quality induced Pluripotent Stem Cell (iPSC) lines that are crucial for advanced research in stem cell biology and regenerative medicine. Our iPSC lines are designed to support cutting-edge research and therapeutic development.
-
With our proprietary TARGATT™ technology for site-specific integration of large DNA fragments, we’ve developed a series of TARGATT™ “master” cell lines, including engineered CHO.
-
Accelerate cell line development for library creation and protein expression with efficient TARGATT™ large knock-in technology.
-
Build cell-based models of disease and accelerate therapeutic development with TARGATT™ large knock-in technology in iPSCs.
-
iPSC-differentiated cell lines combine scalability and biorelevance, enabling precise disease modeling, drug screening, and regenerative research with customizable lineage-specific differentiation options.
-
Co-invented by Applied StemCell’s President and Chief Scientific Officer, Ruby Tsai, Ph.D., and Head of R&D, Alfonso Farruggio, Ph.D., TARGATT™ large knock-in technology enables rapid, efficient, and precise integration of large DNA fragments—up to 20 kb in a single reaction, more in nested reactions—into a specific intergenic locus.
-
Build the most relevant cell line for your studies with the ability to insert 20+ kb of DNA site specifically, in single copy, and at efficiencies approaching 100% after selection.
-
Accelerate your allogeneic development by starting with a hypoimmunogenic iPSC platform reprogrammed from CD34+ cord blood cells.
-
Rapidly advance your allogeneic development with a hypoimmunogenic iPSC platform that has pre-built TARGATT™ large knock-in technology.
-
From precise edits to robust expression, get iPSC genome editing done right — from the experienced innovators in gene editing and iPSC technology.
-
To jump start iPSC derived therapeutic cell product development; achieve reliable and efficient genome integration with our innovative solutions.